Literature DB >> 16006776

What makes MUC1 a tumor antigen?

Uwe Karsten1, Silvia von Mensdorff-Pouilly, Steffen Goletz.   

Abstract

The epithelial mucin 1 (MUC1) is an accepted serum tumor marker and cellular tumor antigen. We discuss recent views on the difference(s) between normal and tumor MUC1, and its implication for the development of cancer vaccines and antibody therapies, with special emphasis on the role of glycosylation. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16006776     DOI： 10.1159/000086956

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  20 in total

1.  A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Authors:  Mahsa Mohebtash; Kwong-Yok Tsang; Ravi A Madan; Ngar-Yee Huen; Diane J Poole; Caroline Jochems; Jacquin Jones; Theresa Ferrara; Christopher R Heery; Philip M Arlen; Seth M Steinberg; Mary Pazdur; Myrna Rauckhorst; Elizabeth C Jones; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 2.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 3.  A systematic review of humoral immune responses against tumor antigens.

Authors:  Miriam Reuschenbach; Magnus von Knebel Doeberitz; Nicolas Wentzensen
Journal:  Cancer Immunol Immunother       Date:  2009-06-28       Impact factor: 6.968

Review 4.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

5.  TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.

Authors:  Sabine Heublein; Klaus Friese; Bernd Kost; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Doris Mayr; Udo Jeschke; Aurelia Vattai
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

6.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Authors:  Sharmila Pejawar-Gaddy; Yogendra Rajawat; Zoe Hilioti; Jia Xue; Daniel F Gaddy; Olivera J Finn; Raphael P Viscidi; Ioannis Bossis
Journal:  Cancer Immunol Immunother       Date:  2010-07-21       Impact factor: 6.968

7.  Random glycopeptide bead libraries for seromic biomarker discovery.

Authors:  Stjepan K Kracun; Emiliano Cló; Henrik Clausen; Steven B Levery; Knud J Jensen; Ola Blixt
Journal:  J Proteome Res       Date:  2010-11-02       Impact factor: 4.466

Review 8.  The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.

Authors:  Lu-Gang Yu
Journal:  Glycoconj J       Date:  2007-04-25       Impact factor: 2.916

9.  Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients.

Authors:  Carlo Fremd; Stefan Stefanovic; Philipp Beckhove; Maria Pritsch; Hendry Lim; Markus Wallwiener; Joerg Heil; Michael Golatta; Joachim Rom; Christof Sohn; Andreas Schneeweiss; Florian Schuetz; Christoph Domschke
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

10.  Identification of early molecular markers for breast cancer.

Authors:  Céline Kretschmer; Anja Sterner-Kock; Friederike Siedentopf; Winfried Schoenegg; Peter M Schlag; Wolfgang Kemmner
Journal:  Mol Cancer       Date:  2011-02-11       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.